Mark Stroh, Ph.D., is a drug development executive with more than two decades of experience bringing new medicines to patients. He and his teams have advanced assets from IND-enabling studies through Phase III, regulatory approval, and post-marketing development, spanning biologics, small molecules, peptides, nucleic acids, and novel formats across several therapeutic areas. Mark is known for his collaborative, cross-functional leadership, drawing on deep expertise in translational and quantitative clinical pharmacology to connect the science to the patient, advance portfolios, and help companies realize the full value of their innovation.